177 related articles for article (PubMed ID: 33774221)
21. Functional Doxorubicin-Loaded Omega-3 Unsaturated Fatty Acids Nanoparticles in Reversing Hepatocellular Carcinoma Multidrug Resistance.
Wang C; Wei X; Shao G
Med Sci Monit; 2021 Feb; 27():e927727. PubMed ID: 33524008
[TBL] [Abstract][Full Text] [Related]
22. Suppression of p53R2 gene expression with specific siRNA sensitizes HepG2 cells to doxorubicin.
Azimi A; Majidinia M; Shafiei-Irannejad V; Jahanban-Esfahlan R; Ahmadi Y; Karimian A; Mir SM; Karami H; Yousefi B
Gene; 2018 Feb; 642():249-255. PubMed ID: 29126924
[TBL] [Abstract][Full Text] [Related]
23. Glycyrrhetinic acid-decorated and reduction-sensitive micelles to enhance the bioavailability and anti-hepatocellular carcinoma efficacy of tanshinone IIA.
Chen F; Zhang J; He Y; Fang X; Wang Y; Chen M
Biomater Sci; 2016 Jan; 4(1):167-82. PubMed ID: 26484363
[TBL] [Abstract][Full Text] [Related]
24. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
25. In-vitro and in-vivo investigation of amygdalin, metformin, and combination of both against doxorubicin on hepatocellular carcinoma.
Mamdouh AM; Khodeer DM; Tantawy MA; Moustafa YM
Life Sci; 2021 Nov; 285():119961. PubMed ID: 34536497
[TBL] [Abstract][Full Text] [Related]
26. SP94 Peptide-Functionalized PEG-PLGA Nanoparticle Loading with Cryptotanshinone for Targeting Therapy of Hepatocellular Carcinoma.
Nie X; Liu Y; Li M; Yu X; Yuan W; Huang S; Ren D; Wang Y; Wang Y
AAPS PharmSciTech; 2020 Apr; 21(4):124. PubMed ID: 32342227
[TBL] [Abstract][Full Text] [Related]
27. Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma.
Dai HY; Chen HY; Lai WC; Hung MC; Li LY
Oncotarget; 2015 Sep; 6(27):23807-19. PubMed ID: 26247632
[TBL] [Abstract][Full Text] [Related]
28. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
29. Self-assembled nanoparticles of reduction-sensitive poly (lactic-co-glycolic acid)-conjugated chondroitin sulfate A for doxorubicin delivery: preparation, characterization and evaluation.
Wang XF; Ren J; He HQ; Liang L; Xie X; Li ZX; Zhao JG; Yu JM
Pharm Dev Technol; 2019 Jul; 24(6):794-802. PubMed ID: 30907676
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of alpha-fetoprotein siRNA inhibits proliferation of SMMC-7721 cells.
Wang YS; Ma XL; Qi TG; Liu XD; Meng YS; Guan GJ
World J Gastroenterol; 2005 Oct; 11(38):6053-5. PubMed ID: 16273624
[TBL] [Abstract][Full Text] [Related]
31.
Lee S; Shin HJ; Noh C; Kim SI; Ko YK; Lee SY; Lim C; Hong B; Yang SY; Kim DW; Lee WH; Kim YH
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073390
[TBL] [Abstract][Full Text] [Related]
32. AUF1 promotes hepatocellular carcinoma progression and chemo-resistance by post-transcriptionally upregulating alpha-fetoprotein expression.
Zhang J; Zhang T; Guan G; Wen J; Chen CC; Liu J; Duan Y; Liu Y; Chen X
Pathol Res Pract; 2023 May; 245():154441. PubMed ID: 37060820
[TBL] [Abstract][Full Text] [Related]
33. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
Huang KW; Lai YT; Chern GJ; Huang SF; Tsai CL; Sung YC; Chiang CC; Hwang PB; Ho TL; Huang RL; Shiue TY; Chen Y; Wang SK
Biomacromolecules; 2018 Jun; 19(6):2330-2339. PubMed ID: 29808997
[TBL] [Abstract][Full Text] [Related]
34. Specific cellular internalization and pH-responsive behavior of doxorubicin loaded PLGA-PEG nanoparticles targeted with anti EGFRvIII antibody.
Eivazi N; Rahmani R; Paknejad M
Life Sci; 2020 Nov; 261():118361. PubMed ID: 32861796
[TBL] [Abstract][Full Text] [Related]
35. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
[TBL] [Abstract][Full Text] [Related]
36. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of Kinesin spindle protein inhibits proliferation, induces apoptosis and increases chemosensitivity in hepatocellular carcinoma cells.
Doan CC; Doan NT; Nguyen QH; Nguyen MH; Do MS; Le VD
Iran Biomed J; 2015; 19(1):1-16. PubMed ID: 25605484
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin and farnesol co-encapsulated PLGA nano-particles demonstrate enhanced anti-cancer potential against hepatocellular carcinoma cells in vitro.
Mondal J; Khuda-Bukhsh AR
Mol Biol Rep; 2020 May; 47(5):3615-3628. PubMed ID: 32314187
[TBL] [Abstract][Full Text] [Related]
39. Fabrication, optimization, and characterization of umbelliferone β-D-galactopyranoside-loaded PLGA nanoparticles in treatment of hepatocellular carcinoma: in vitro and in vivo studies.
Kumar V; Bhatt PC; Rahman M; Kaithwas G; Choudhry H; Al-Abbasi FA; Anwar F; Verma A
Int J Nanomedicine; 2017; 12():6747-6758. PubMed ID: 28932118
[TBL] [Abstract][Full Text] [Related]
40. pH-sensitive polymeric nanoparticles for co-delivery of doxorubicin and curcumin to treat cancer via enhanced pro-apoptotic and anti-angiogenic activities.
Zhang J; Li J; Shi Z; Yang Y; Xie X; Lee SM; Wang Y; Leong KW; Chen M
Acta Biomater; 2017 Aug; 58():349-364. PubMed ID: 28455219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
